成都科岭源医药技术有限公司

Chengdu Kelinyuan Pharmaceutical Technology is a clinical-stage biotechnology company headquartered in the Tianfu International Bio-Town of Chengdu, China. The company specializes in the research and development of innovative small molecule drugs, with a primary focus on metabolic disorders and oncology. Its lead candidate, KLY-011, is a highly selective URAT1 inhibitor currently in clinical development for the treatment of hyperuricemia and gout. Kelinyuan aims to provide more effective and safer therapeutic options for patients through its proprietary drug discovery platform and efficient clinical execution. The company has successfully secured funding from prominent investors like HighLight Capital to advance its pipeline.